Association of C‐MYC amplification with progression from the in situ to the invasive stage in C‐MYC‐amplified breast carcinomas
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Human carcinoma in situ of the breast already demonstrates genomic changes found in invasive lesions. However, no specific genetic alterations have previously been identified that are associated with progression from the in situ to the invasive stage. By comparative genomic hybridization (CGH) and fluorescence in situ hybridization (FISH) analysis of an invasive breast carcinoma with a large associated in situ component, high‐level amplification of C‐MYC was found in the invasive component only. To determine the frequency of this correlation in a panel of 188 invasive breast carcinomas, 18 additional cases with C‐MYC amplification were identified. Nine of these cases had a detectable adjacent in situ component. FISH analysis demonstrated increased (>5) C‐MYC signals per nucleus in seven invasive components and increased (>4) C‐MYC/centromere 8 signal ratios in five of these. None of the associated in situ components demonstrated these increases. The minimal amplified region was defined at 8q24.13‐8qter. C‐MYC amplification was correlated with overexpression of C‐MYC and two of its target genes, TERT and FBL. Thus, C‐MYC amplification is the first identified genetic alteration that is associated with progression from the in situ to the invasive stage of breast carcinoma. Copyright © 2003 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct activation of TERT transcription by c-MYC
Wu, K.-J., Grandori, C., Amacker, M., Simon-Vermot, N., Polack, A., Lingner, J., & Dalla-Favera, R. (1999) · Nature Genetics · doi:10.1038/6010 · Cited by 893
Deregulated expression of c-Myc depletes epidermal stem cells
Waikel, R. L., Kawachi, Y., Waikel, P. A., Wang, X.-J., & Roop, D. R. (2001) · Nature Genetics · doi:10.1038/88889 · Cited by 318
Cited by
The Myc oncoprotein as a therapeutic target for human cancer
Vita, M., & Henriksson, M. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.015 · Cited by 552
Xu, J., Chen, Y., & Olopade, O. I. (2010) · Genes & Cancer · doi:10.1177/1947601910378691 · Cited by 382
Breast cancer precursors revisited: molecular features and progression pathways
Lopez‐Garcia, M. A., Geyer, F. C., Lacroix‐Triki, M., Marchió, C., & Reis‐Filho, J. S. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03568.x · Cited by 347
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
Progression from ductal carcinoma in situ to invasive breast cancer: Revisited
Cowell, C. F., Weigelt, B., Sakr, R. A., Ng, C. K. Y., Hicks, J., King, T. A., & Reis-Filho, J. S. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.07.005 · Cited by 257
Geyer, F. C., Weigelt, B., Natrajan, R., Lambros, M. B., de Biase, D., Vatcheva, R., Savage, K., Mackay, A., Ashworth, A., & Reis‐Filho, J. S. (2010) · The Journal of Pathology · doi:10.1002/path.2675 · Cited by 233
Myc regulates keratinocyte adhesion and differentiation via complex formation with Miz1
Gebhardt, A., Frye, M., Herold, S., Benitah, S. A., Braun, K., Samans, B., Watt, F. M., Elsässer, H.-P., & Eilers, M. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200506057 · Cited by 118
“Keratinocytes were cultured on a dermal equivalent of dead DED from adult breast skin ( Rikimaru et al., 1997 ).”
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
Metadata
- Authors
- Robanus‐Maandag, E. C., Bosch, C. A., Kristel, P. M., Hart, A. A., Faneyte, I. F., Nederlof, P. M., Peterse, J. L., & van de Vijver, M. J.
- Venue
- The Journal of Pathology
- Publisher
- Wiley
- Published
- 2003-04-14
- Volume
- 201
- Issue
- 1
- Pages
- 75-82
- ISSN
- 0022-3417 (ISSN-L)
- 1096-9896
- OpenAlex
- W1968958091
- Cited by
- 93
- References
- 2
- FWCI
- 4.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.